All In Biotech

Drug Trial Radar · NCT05110638

Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis

A Phase 1, Open-Label Study Evaluating the Pharmacokinetics, Absorption, Safety and Tolerability With Maximal Use of SKX-16 (Luliconazole 10% Solution) in Subjects With Moderate to Severe Distal Subungual Onychomycosis

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Sep 22, 2021

Primary completion

May 30, 2022

Study completion Jun 6, 2022

Sponsor

Lead sponsor
SATO Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to determine the pharmacokinetics, systemic exposure, safety and tolerability after daily topical application of SKX-16 (Luliconazole 10% Solution) for duration of 29 days in a maximal use setting in adults with moderate to severe distal subungual onychomycosis of the toenails.

Conditions

  • Onychomycosis of Toenail

Interventions

  • SKX-16 (Luliconazole 10% Solution)Drug

    SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameters for the systemic absorption of luliconazole - AUC0-24hTime frame: 36 days
  2. PK parameters for the systemic absorption of luliconazole - AUC0-∞Time frame: 36 days
  3. PK parameters for the systemic absorption of luliconazole - CmaxTime frame: 36 days
  4. PK parameters for the systemic absorption of luliconazole - TmaxTime frame: 36 days
  5. PK parameters for the systemic absorption of luliconazole - t1/2Time frame: 36 days
  6. PK parameters for the systemic absorption of luliconazole - kelTime frame: 36 days
  7. Safety Assessment - Local Application Site Tolerability Assessment (LASTA)Time frame: 36 days
  8. Safety Assessment - Adverse EventsTime frame: 36 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • J&S Studies, Inc.

    College Station, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.